Leiden University Medical Center

lumc.nlc

The LUMC is a center of medical innovation that aims to improve patient care through scientific research. It trains doctors, specialist care providers and researchers to contribute to this. In addition to general patient care, the LUMC offers specialist treatments that can only be performed in a limited number of medical centers. The LUMC is particularly distinguished as a referral center for complex medical questions that have no ready-made answers. Scientists and doctors work together on a better understanding of diseases and new treatment methods.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

TAYSHA GENE THERAPIES ANNOUNCES NEW ADDITIONS TO LEADERSHIP TEAM TO DEEPEN MANUFACTURING AND COMMUNICATIONS CAPABILITIES

Taysha | December 30, 2020

news image

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-driven gene therapy organization focused in on creating and commercializing AAV-based quality treatments for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today reported new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relatio...

Read More

Cell and Gene Therapy

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

news image

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More

Medical, Industry Outlook

NONA BIOSCIENCES ANNOUNCES BUSINESS UPDATE OF COLLABORATION ON ANTIBODY DRUG CONJUGATE (ADC) WITH DUALITYBIO

PRNewswire | July 14, 2023

news image

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM) announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors. This program wa...

Read More

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

news image

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More
news image

Cell and Gene Therapy

TAYSHA GENE THERAPIES ANNOUNCES NEW ADDITIONS TO LEADERSHIP TEAM TO DEEPEN MANUFACTURING AND COMMUNICATIONS CAPABILITIES

Taysha | December 30, 2020

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-driven gene therapy organization focused in on creating and commercializing AAV-based quality treatments for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today reported new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relatio...

Read More
news image

Cell and Gene Therapy

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More
news image

Medical, Industry Outlook

NONA BIOSCIENCES ANNOUNCES BUSINESS UPDATE OF COLLABORATION ON ANTIBODY DRUG CONJUGATE (ADC) WITH DUALITYBIO

PRNewswire | July 14, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM) announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors. This program wa...

Read More
news image

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us